Organon's women's health and biosimilar portfolios are positioned to offset pressure on older, off-patent brands and gradually restore margins. The company recently received FDA approval for extended duration use of NEXPLANON with a new REMS safety program. In January 2026, Organon became a potential acquisition target when Sun Pharmaceutical Industries submitted a non-binding proposal to acquire the company.
Cyborg Score Rationale
The company experienced a sharp swing from full-year 2024 net income of US$864 million to 2025 net income of US$187 million due to pricing pressure, loss of exclusivity for drugs such as Atozet, and ongoing cost challenges. While women's health growth and biosimilars present upside, near-term headwinds from patent cliff and pricing pressures create uncertainty.
Top Insights
Patent cliff risk: Loss of exclusivity for Atozet (second-largest product) and other off-patent drugs are major margin pressures
FDA approval catalyst: Nexplanon extended duration (now 5-year use) could drive women's health revenue growth
Acquisition interest: Sun Pharma's nonbinding offer signals strategic value in women's health and biosimilars portfolios
Geographic exposure: Majority of revenue from Europe and Canada; US market represents smaller portion, limiting direct US tariff exposure
Named Competitors
Women's Health & Biosimilars — Large-cap pharma with diverse portfolio
Women's Health & General Medicines — High-growth innovative pharmaceutical company
Established Branded Pharma — Global pharmaceutical competitor
Recent Developments
(January 2026) Sun Pharmaceutical submitted nonbinding $10-14B all-cash acquisition proposal for Organon
(January 2026) FDA approved extended-duration NEXPLANON use (3 to 5 years) with new REMS safety program
(February 2026) Q4 2025 earnings showed net loss of US$205M; 2026 revenue guidance maintained at ~US$6.2B
Open the full interactive Organon & Co. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.